论文部分内容阅读
本文总结25年间长期积累的垂体厌色细胞瘤81例放疗的临床经验。全组总控制率达71.6％相当于国外最好水平。从本组长期随诊的结果看,剂量不宜过低或过高,大体“适宜剂量”应为3,OOO—4,000拉得,但又不要千篇一律。由于本组的“综合治疗”组和放射治疗组二者疗效差别不大,这就进一步肯定了放疗的制瘤价值,可以认为放疗适应症范围应予扩大。除有急剧的视神经受压表现者应及时手术减压外,均应放疗先行。手术的任务仅是减压,制瘤要靠放射,由于垂体瘤手术常不能切净,放疗是必行的。问题在于掌握照射的时机和正确地给予剂量才能提高疗效,一味地追求大剂量不会有好的疗效。
This article summarizes the 25 years of long-term accumulation of pituitary anastomosis tumor clinical experience of 81 cases of radiotherapy. The total control rate of 71.6% of the whole group equivalent to the best level abroad. From the group’s long-term follow-up results, the dose should not be too low or too high, the general “appropriate dose” should be 3,000-4,000 pull, but not stereotyped. As the group of “comprehensive treatment” and radiotherapy group two little difference between the efficacy, which further affirmed the value of radiotherapy tumor, we can think that the scope of radiotherapy should be expanded. In addition to a sharp optic nerve compression performance should be prompt surgical decompression, should be treated first. The task of surgery is only decompression, tumorigenesis rely on radiation, due to pituitary tumor often can not cut the net, radiotherapy is imperative. The problem is to grasp the timing of irradiation and the right dose to improve the efficacy, blind pursuit of high doses will not have a good effect.